[
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
    "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
    "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986479,
      "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
      "id": 136160874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
      "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a"
    }
  },
  {
    "ts": null,
    "headline": "Helfie AI Expands Executive Team to Drive Global Health Tech Growth",
    "summary": "By Daniella Parra Health tech company Helfie AI has appointed Stefan Kulik as Chief Operating Officer and Rania Awad as Chief Strategy Officer, strengthening its leadership team as it prepares for the global consumer launch of its AI-powered mobile health check platform, the company said. Kulik, with leadership experience at PepsiCo and Johnson & Johnson, […]",
    "url": "https://finnhub.io/api/news?id=7620d5f17d130c9ccbe3729179caab727a65ebccf54aa8d6614a2f77bee7bec4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753980493,
      "headline": "Helfie AI Expands Executive Team to Drive Global Health Tech Growth",
      "id": 136155115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "By Daniella Parra Health tech company Helfie AI has appointed Stefan Kulik as Chief Operating Officer and Rania Awad as Chief Strategy Officer, strengthening its leadership team as it prepares for the global consumer launch of its AI-powered mobile health check platform, the company said. Kulik, with leadership experience at PepsiCo and Johnson & Johnson, […]",
      "url": "https://finnhub.io/api/news?id=7620d5f17d130c9ccbe3729179caab727a65ebccf54aa8d6614a2f77bee7bec4"
    }
  },
  {
    "ts": null,
    "headline": "TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales",
    "summary": "TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.",
    "url": "https://finnhub.io/api/news?id=b42ff2736329986f8a6a8900221a35eb8a538ecbc021c2318d76710ad9740645",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753979880,
      "headline": "TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales",
      "id": 136160913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.",
      "url": "https://finnhub.io/api/news?id=b42ff2736329986f8a6a8900221a35eb8a538ecbc021c2318d76710ad9740645"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View",
    "summary": "ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.",
    "url": "https://finnhub.io/api/news?id=696c72dc71aabbbec36656fd46ded06ed7ce669ad6466edc0fba483ce7ae8c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753978500,
      "headline": "AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View",
      "id": 136160914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.",
      "url": "https://finnhub.io/api/news?id=696c72dc71aabbbec36656fd46ded06ed7ce669ad6466edc0fba483ce7ae8c52"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Equity Income Fund Q2 2025 Commentary",
    "summary": "Franklin Equity Income Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=d06405870fbee6be2cbb04adc3ca63d57ac7f39f92fdbc49c5833f49e9fe8522",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753958700,
      "headline": "Franklin Equity Income Fund Q2 2025 Commentary",
      "id": 136153521,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d06405870fbee6be2cbb04adc3ca63d57ac7f39f92fdbc49c5833f49e9fe8522"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Equity Income SMA Q2 2025 Commentary",
    "summary": "JPMorgan Chase was a leading contributor to ï¬nancials sector performance. Read more here.",
    "url": "https://finnhub.io/api/news?id=633d7e5919c1d82b23a104288e75eceaf6983b5068b1d273b84f1e53d190d8a5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753957800,
      "headline": "Franklin Equity Income SMA Q2 2025 Commentary",
      "id": 136153265,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161896289/image_2161896289.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "JPMorgan Chase was a leading contributor to ï¬nancials sector performance. Read more here.",
      "url": "https://finnhub.io/api/news?id=633d7e5919c1d82b23a104288e75eceaf6983b5068b1d273b84f1e53d190d8a5"
    }
  },
  {
    "ts": null,
    "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
    "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
    "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954260,
      "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
      "id": 136151783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
      "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02"
    }
  }
]